A recent report from France suggested an association between the use of cobalt-chrome (CoCr) femoral heads in total hip arthroplasties (THAs) and an increased risk of dilated cardiomyopathy and heart failure. CoCr is a commonly used material in orthopaedic implants. If the reported association is causal, the consequences would be significant given the millions of joint arthroplasties and other orthopaedic procedures in which CoCr is used annually. We examined whether CoCr-containing THAs were associated with an increased risk of all-cause mortality, heart outcomes, cancer, and neurodegenerative disorders in a large national database. Data from the National Joint Registry was linked to NHS English hospital inpatient episodes for 374,359 primary THAs with up to 14.5 years' follow-up. We excluded any patients with bilateral THAs, knee arthroplasties, indications other than osteoarthritis, aged under 55 years, and diagnosis of one or more outcome of interest before THA. Implants were grouped as either containing CoCr or not containing CoCr. The association between implant construct and the risk of all-cause mortality and incident heart failure, cancer, and neurodegenerative disorders was examined.Aims
Methods
Most hip fractures treated with modern internal
fixation techniques will heal. However, failures occasionally occur and
require revision procedures. Salvage strategies employed during
revision are based on whether the fixation failure occurs in the
femoral neck, or in the intertrochanteric region. Patient age and
remaining bone stock also influence decision making. For fractures
in young patients, efforts are generally focused on preserving the
native femoral head via osteotomies and repeat internal fixation.
For failures in older patients, some kind of hip replacement is
usually selected. Disuse osteopenia, deformity, bone loss, and stress-risers
from previous
Hip arthrodesis remains a viable surgical technique
in well selected patients, typically the young manual labourer with
isolated unilateral hip disease. Despite this, its popularity with
patients and surgeons has decreased due to the evolution of hip
replacement, and is seldom chosen by young adult patients today.
The surgeon is more likely to encounter a patient who requests conversion
to total hip replacement (THR). The most common indications are
a painful pseudarthrosis, back pain, ipsilateral knee pain or contralateral
hip pain. Occasionally the patient will request conversion because
of difficulty with activities of daily living, body image and perceived
cosmesis. The technique of conversion and a discussion of the results
are presented. Cite this article:
We determined the midterm survival, incidence
of peri-prosthetic fracture and the enhancement of the width of
the femur when combining struts and impacted bone allografts in
24 patients (25 hips) with severe femoral bone loss who underwent
revision hip surgery. The pre-operative diagnosis was aseptic loosening
in 16 hips, second-stage reconstruction in seven, peri-prosthetic
fracture in one and stem fracture in one hip. A total of 14 hips
presented with an Endoklinik grade 4 defect and 11 hips a grade
3 defect. The mean pre-operative Merle D’Aubigné and Postel score
was 5.5 points (1 to 8). The survivorship was 96% (95% confidence interval 72 to 98) at
a mean of 54.5 months (36 to 109). The mean functional score was
17.3 points (16 to 18). One patient in which the strut did not completely
bypass the femoral defect was further revised using a long cemented
stem due to peri-prosthetic fracture at six months post-operatively.
The mean subsidence of the stem was 1.6 mm (1 to 3). There was no
evidence of osteolysis, resorption or radiolucencies during follow-up
in any hip. Femoral width was enhanced by a mean of 41% (19% to
82%). A total of 24 hips had partial or complete bridging of the
strut allografts. This combined biological method was associated with a favourable
survivorship, a low incidence of peri-prosthetic fracture and enhancement
of the width of the femur in revision total hip replacement in patients
with severe proximal femoral bone loss.
We have updated our previous randomised controlled trial comparing release of chromium (Cr) and cobalt (Co) ions and included levels of titanium (Ti) ions. We have compared the findings from 28 mm metal-on-metal total hip replacement, performed using titanium CLS/Spotorno femoral components and titanium AlloFit acetabular components with Metasul bearings, with Durom hip resurfacing using a Metasul articulation or bearing and a titanium plasma-sprayed coating for fixation of the acetabular component. Although significantly higher blood ion levels of Cr and Co were observed at three months in the resurfaced group than in total hip replacement, no significant difference was found at two years post-operatively for Cr, 1.58 μg/L and 1.62 μg/L respectively (p = 0.819) and for Co, 0.67 μg/L and 0.94 μg/L respectively (p = 0.207). A steady state was reached at one year in the resurfaced group and after three months in the total hip replacement group. Interestingly, Ti, which is not part of the bearing surfaces with its release resulting from metal corrosion, had significantly elevated ion levels after implantation in both groups. The hip resurfacing group had significantly higher Ti levels than the total hip replacement group for all periods of follow-up. At two years the mean blood levels of Ti ions were 1.87 μg/L in hip resurfacing and and 1.30 μg/L in total hip replacement (p = 0.001). The study confirms even with different bearing diameters and clearances, hip replacement and 28 mm metal-on-metal total hip replacement produced similar Cr and Co metal ion levels in this randomised controlled trial study design, but apart from wear on bearing surfaces, passive corrosion of exposed metallic surfaces is a factor which influences ion concentrations. Ti plasma spray coating the acetabular components for hip resurfacing produces significantly higher release of Ti than Ti grit-blasted surfaces in total hip replacement.
We report the outcome at ten to 15 years of two-stage revision for hip infection in 99 patients using the Prostalac articulated hip spacer system. All the patients were contacted to determine their current functional and infection status using the Oxford-12, Short form-12, and Western Ontario and McMaster University Osteoarthritis Index questionnaires. A total of 11 of the 99 patients had a further infection, of whom seven responded to repeat surgery with no further sequelae. The mean interval between the stages was five months (1 to 36). We were able to review 48 living patients, with a mean age of 72 years (46 to 86), 34 (71%) of whom provided health-related quality-of-life outcome scores. The mean follow-up was 12 years (10 to 15). The long-term success rate was 89% and with additional surgery this rose to 96%. The mean global Western Ontario and McMaster University Osteoarthritis Index score was 80.6 ( Two-stage revision for hip infection using a Prostalac interim spacer offers a predictable and lasting solution for patients with this difficult problem.
Conventional treatment of mild slipped capital femoral epiphysis consists of fixation Between October 1984 and December 1995 we treated 16 patients for unilateral mild slipped capital femoral epiphysis by fixation While our clinical data favours conventional treatment, our radiological findings are in support of restoring the anatomy of the proximal femur to avoid or delay the development of femoroacetabular impingement following mild slipped capital femoral epiphysis.